Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update

Frontiers in gastroenterology (Lausanne, Switzerland) Pub Date : 2022-10-17 DOI:10.3389/fgstr.2022.1022530

L. Masi, C. Ciuffini, V. Petito, L. Pisani, L. Lopetuso, C. Graziani, D. Pugliese, L. Laterza, P. Puca, F. Di Vincenzo, M. Pizzoferrato, D. Napolitano, L. Turchini, V. Amatucci, E. Schiavoni, G. Privitera, L. Minordi, M. C. Mentella, A. Papa, A. Armuzzi, A. Gasbarrini, F. Scaldaferri

{"title":"Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update","authors":"L. Masi, C. Ciuffini, V. Petito, L. Pisani, L. Lopetuso, C. Graziani, D. Pugliese, L. Laterza, P. Puca, F. Di Vincenzo, M. Pizzoferrato, D. Napolitano, L. Turchini, V. Amatucci, E. Schiavoni, G. Privitera, L. Minordi, M. C. Mentella, A. Papa, A. Armuzzi, A. Gasbarrini, F. Scaldaferri","doi":"10.3389/fgstr.2022.1022530","DOIUrl":null,"url":null,"abstract":"Inflammatory bowel diseases (IBD) are chronic disabling conditions with a complex and multifactorial etiology, which is still not completely understood. In the last 20 years, anti-TNF-α antagonists have revolutionized the treatment of IBD, but many patients still do not respond or experience adverse events. Therefore, new biological therapies and small molecules, targeting several different pathways of gut inflammation, have been developed of which some have already been introduced in clinical practice while many others are currently investigated. Moreover, therapeutic procedures such as leukocytapheresis, fecal microbiota transplant and stem cell transplantation are currently being investigated for treating IBD. Lastly, complementary and alternative medicine has become a field of interest for gastroenterologist to reduce symptom burden in IBD patients. In this comprehensive and updated review, a novel classification of current and developing drugs is provided.","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in gastroenterology (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fgstr.2022.1022530","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Inflammatory bowel diseases (IBD) are chronic disabling conditions with a complex and multifactorial etiology, which is still not completely understood. In the last 20 years, anti-TNF-α antagonists have revolutionized the treatment of IBD, but many patients still do not respond or experience adverse events. Therefore, new biological therapies and small molecules, targeting several different pathways of gut inflammation, have been developed of which some have already been introduced in clinical practice while many others are currently investigated. Moreover, therapeutic procedures such as leukocytapheresis, fecal microbiota transplant and stem cell transplantation are currently being investigated for treating IBD. Lastly, complementary and alternative medicine has become a field of interest for gastroenterologist to reduce symptom burden in IBD patients. In this comprehensive and updated review, a novel classification of current and developing drugs is provided.

查看原文本刊更多论文

炎症性肠病的创新、补充和替代疗法:2020年的广泛更新

炎症性肠病(IBD)是一种慢性致残疾病，具有复杂的多因素病因，目前仍未完全了解。在过去的20年里，抗tnf -α拮抗剂已经彻底改变了IBD的治疗，但许多患者仍然没有反应或经历不良事件。因此，针对几种不同肠道炎症途径的新的生物疗法和小分子已经被开发出来，其中一些已经被引入临床实践，而许多其他的正在研究中。此外，目前正在研究白细胞清除、粪便微生物群移植和干细胞移植等治疗方法来治疗IBD。最后，补充和替代医学已成为胃肠病学家感兴趣的领域，以减轻IBD患者的症状负担。在这篇全面和最新的综述中，提供了当前和正在开发的药物的新分类。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in gastroenterology (Lausanne, Switzerland)

自引率

0.00%

发文量